VEGFA and neoplasm: Meanwhile, the double-blind, placebo-controlled, phase III INTEGRATE IIa trial comparing REGO with placebo using a 2 : 1 randomisation, stratified by tumour location (gastro-oesophageal junction versus gastric), geographic region (Asia versus rest of the world), and prior VEGF inhibitors, examined REGO efficacy in terms of OS.